Pulmonx (LUNG) Equity Average (2019 - 2025)

Pulmonx (LUNG) has 7 years of Equity Average data on file, last reported at $57.1 million in Q4 2025.

• Quarterly Equity Average fell 36.49% year-over-year to $57.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $57.1 million (down 36.49% YoY) and the FY2025 annual result came in at $70.0 million, down 31.45% from the prior year.
• Equity Average fell to $57.1 million in Q4 2025 per LUNG's latest filing, from $64.6 million in the prior quarter.
• Across five years, Equity Average topped out at $221.1 million in Q1 2021 and bottomed at $57.1 million in Q4 2025.
• The 5-year median for Equity Average is $134.4 million (2023), against an average of $137.7 million.
• The widest annual swing landed in 2021, when Equity Average soared 1958.03%; it then sank 36.49% in 2025.
• Tracing LUNG's Equity Average over 5 years: stood at $198.0 million in 2021, then decreased by 19.84% to $158.7 million in 2022, then retreated by 23.13% to $122.0 million in 2023, then retreated by 26.36% to $89.9 million in 2024, then slumped by 36.49% to $57.1 million in 2025.
• Per Business Quant, the three latest LUNG Equity Average figures stand at $57.1 million (Q4 2025), $64.6 million (Q3 2025), and $73.4 million (Q2 2025).

Peer Comparison